Stakeholders want more opportunities to discuss MIDD with FDA
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesClinical TrialsGuidancePharmaceuticalsPreclinical studyProduct developmentRegulatory Intelligence/PolicyRWE/RWDUnited StatesUS Food and Drug Administration (FDA)